Compare Davita Inc (DVA) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs General Motors Company — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while General Motors Company trades at $82.73 (market cap $72.17B). The key difference: General Motors Company is far larger — about 6.4× Davita Inc's market cap, and General Motors Company pays a 0.88% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and General Motors Company for 83 Days on average.
| DVA | GM | |
|---|---|---|
Market Cap | $11.29B | $72.17B |
Volume | 582,204 | 4,900,304 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $90.30 |
52-Week Low | $103.87 | $55.35 |
Typical Hold Time | 114 Days | 83 Days |
Enterprise Value | $24.01B | $175.15B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
General Motors (GM) trades at $82.25, up 1.56% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong cash flow ($26.9B operating cash flow in 2025) but declining profit margins (1.05% net margin). Recent Q3 2026 sales declined 5.5% as EV demand weakens, though regulatory savings of $20.4B through 2031 provide some offset. Analyst consensus remains bullish with a $102.08 price target representing 24% upside potential.
GM faces near-term headwinds from declining vehicle sales and margin pressure, but long-term value exists through cost savings initiatives and strong cash generation. The stock trades at attractive valuations (P/S 0.42x) with 67% analyst buy ratings, though competitive pressure from Asian automakers and EV transition challenges present significant execution risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
